{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T22:10:52Z","timestamp":1783548652401,"version":"3.55.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"National Research Foundation of Korea (NRF) Grant funded by the Korean Government [MIST]","award":["NRF-2018R1A5A2025964"],"award-info":[{"award-number":["NRF-2018R1A5A2025964"]}]},{"name":"Creative-Pioneering Researchers Program through Seoul National University (SNU) The Seoul National University Hospital Medical Research Collaborating Center","award":["none"],"award-info":[{"award-number":["none"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Among Asian countries, South Korea was the first to approve liraglutide as a treatment for obesity. Thus, the clinical effectiveness of liraglutide has not been studied in Asian populations.<\/jats:p>\n            <jats:p>In this study, we retrospectively analyzed obese patients [body mass index (BMI) &gt;27\u200akg\/m<jats:sup>2<\/jats:sup>] who were treated with liraglutide between March 2018 and March 2019 in a single clinic. Weight, BMI, HbA1c, and clinical data were collected before liraglutide treatment. Changes in body weight and composition and their relationships with clinical variables were examined at re-prescription dates within 30, 60, 90, and 180 days.<\/jats:p>\n            <jats:p>A total of 169 subjects were studied. The average age was 41.5 years, and 42% of the subjects were male. The average weight was 85.2\u200akg, and the average BMI was 30.8\u200akg\/m<jats:sup>2<\/jats:sup>. Weight reduction was significant (\u20135.5\u200a\u00b1\u200a3.4\u200akg, 30 days: \u20133.2\u200a\u00b1\u200a1.8\u200akg, 60 days: \u20134.5\u200a\u00b1\u200a2.3\u200akg, 90 days: \u20136.3\u200a\u00b1\u200a2.6\u200akg, 180 days: \u20137.8\u200a\u00b1\u200a3.5\u200akg) during the follow-up period and increased with longer treatment time (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001). The percentages of subjects that showed \u2265 5% and \u2265 10% body weight reduction were 62.1% and 17.2%, respectively. In the body composition analysis, skeletal muscle weight loss was \u20133.56\u200a\u00b1\u200a29.7%, which was significantly smaller than fat weight loss of \u201311.06\u200a\u00b1\u200a10.4% (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.03). Weight loss was not significantly related to age, sex, baseline BMI, baseline HbA1c, smoking status, alcohol consumption, coffee intake.<\/jats:p>\n            <jats:p>In conclusion, Liraglutide treatment led to meaningful weight loss in South Korean patients, and fat mass reduction was prominent during treatment. Furthermore, liraglutide showed greater clinical effectiveness with longer treatment time.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000023780","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T16:08:34Z","timestamp":1610640514000},"page":"e23780","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":25,"title":["Clinical effectiveness of liraglutide on weight loss in South Koreans"],"prefix":"10.1097","volume":"100","author":[{"given":"Joon Seok","family":"Park","sequence":"first","affiliation":[{"name":"Seoul National University College of Medicine"},{"name":"Seoul Happiness Clinic of Internal Medicine, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieun","family":"Kwon","sequence":"additional","affiliation":[{"name":"Seoul Happiness Clinic of Internal Medicine, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0593-6978","authenticated-orcid":false,"given":"Hyung Jin","family":"Choi","sequence":"additional","affiliation":[{"name":"Seoul National University College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5839-6576","authenticated-orcid":false,"given":"Changhyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Seoul Happiness Clinic of Internal Medicine, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMra1514009","article-title":"Mechanisms, pathophysiology, and management of obesity","volume":"376","author":"Heymsfield","year":"2017","journal-title":"N Engl J Med"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1467-789X.2007.00393.x","article-title":"Long-term weight loss effects on all cause mortality in overweight\/obese populations","volume":"8","author":"Poobalan","year":"2007","journal-title":"Obes Rev"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1177\/1359105312451865","article-title":"Understanding the relationship between weight loss, emotional well-being and health-related quality of life in patients attending a specialist obesity weight management service","volume":"18","author":"Wright","year":"2013","journal-title":"J Health Psychol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"g2646","DOI":"10.1136\/bmj.g2646","article-title":"Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials","volume":"348","author":"Dombrowski","year":"2014","journal-title":"BMJ"},{"issue":"(1 Suppl)","key":"R5-20250504","doi-asserted-by":"crossref","first-page":"222s","DOI":"10.1093\/ajcn\/82.1.222S","article-title":"Long-term weight loss maintenance","volume":"82","author":"Wing","year":"2005","journal-title":"Am J Clin Nutr"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/oby.20394","article-title":"Why do we need drugs to treat the patient with obesity?","volume":"21","author":"Bray","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"323rv2","DOI":"10.1126\/scitranslmed.aad1811","article-title":"New therapeutic approaches for the treatment of obesity","volume":"8","author":"Saltiel","year":"2016","journal-title":"Sci Transl Med"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/ijo.2013.162","article-title":"Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults","volume":"38","author":"van Can","year":"2014","journal-title":"Int J Obes (Lond)"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s40265-015-0408-8","article-title":"Liraglutide: a review of its use in the management of obesity","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0\u200amg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes (Lond)"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/oby.22462","article-title":"Real-world clinical effectiveness of liraglutide 3.0\u200amg for weight management in Canada","volume":"27","author":"Wharton","year":"2019","journal-title":"Obesity (Silver Spring)"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1001\/jama.2009.726","article-title":"Diabetes in Asia: epidemiology, risk factors, and pathophysiology","volume":"301","author":"Chan","year":"2009","journal-title":"JAMA"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"621","DOI":"10.12965\/jer.1836284.142","article-title":"The reproducibility and validity verification for body composition measuring devices using bioelectrical impedance analysis in Korean adults","volume":"14","author":"Yang","year":"2018","journal-title":"J Exerc Rehabil"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13098-017-0242-0","article-title":"The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0\u200amg","volume":"9","author":"Mancini","year":"2017","journal-title":"Diabetol Metab Syndr"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1002\/oby.21629","article-title":"Early weight loss with liraglutide 3.0\u200amg predicts 1-year weight loss and is associated with improvements in clinical markers","volume":"24","author":"Fujioka","year":"2016","journal-title":"Obesity (Silver Spring)"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"e1339","DOI":"10.1111\/ijcp.13399","article-title":"Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: the XENSOR Study","volume":"73","author":"Gorgojo-Martinez","year":"2019","journal-title":"Int J Clin Pract"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","article-title":"New trends on obesity and NAFLD in Asia","volume":"67","author":"Fan","year":"2017","journal-title":"J Hepatol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.schres.2008.05.011","article-title":"The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance","volume":"103","author":"Lykkegaard","year":"2008","journal-title":"Schizophr Res"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"219","DOI":"10.14740\/jocmr3647","article-title":"Liraglutide reduces visceral and intrahepatic fat without significant loss of muscle mass in obese patients with type 2 diabetes: a prospective case series","volume":"11","author":"Ishii","year":"2019","journal-title":"J Clin Med Res"},{"key":"R23-20250504","first-page":"407","article-title":"Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus","volume":"10","author":"Rondanelli","year":"2016","journal-title":"Patient Prefer Adher"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"158","DOI":"10.7570\/jomes.2019.28.3.158","article-title":"The role of anti-obesity medication in prevention of diabetes and its complications","volume":"28","author":"Oh","year":"2019","journal-title":"J Obes Metab Syndr"},{"issue":"(Pt B)","key":"R25-20250504","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.neuropharm.2018.01.013","article-title":"GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence","volume":"136","author":"Jerlhag","year":"2018","journal-title":"Neuropharmacology"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2174\/1381612825666190701155737","article-title":"Liraglutide for the treatment of obesity: analyzing published reviews","volume":"25","author":"Pastor","year":"2019","journal-title":"Curr Pharm Des"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/cpt.359","article-title":"Considerations for the analysis of longitudinal electronic health records linked to claims data to study the effectiveness and safety of drugs","volume":"100","author":"Lin","year":"2016","journal-title":"Clin Pharmacol Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023780","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:23:48Z","timestamp":1746339828000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023780"}},"subtitle":["First real-world retrospective data on Saxenda in Asia"],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000023780","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,15]]},"assertion":[{"value":"2020-01-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}